ABT-199 (Venetoclax), a selective BCL-2 inhibitor, has demonstrated efficacy in treating BCL-2-dependent hematological cancers [74] and is FDA-approved [24,75]. This evidence concerns the gene BCL2 and hematopoietic and lymphoid cell neoplasm.